This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01347/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01347/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB01347/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01347/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01347/identifier/pubchem-compound/

Statements

Subject Item
n2:DB01347
rdf:type
n3:Drug
n3:description
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism.(10579749)
n3:group
approved
n3:indication
Saprisartan is used in the treatment of hypertension and heart failure.
owl:sameAs
n6:DB01347 n8:DB01347
dcterms:title
Saprisartan
adms:identifier
n10:PA164746338 n11:54892 n12:46508176 n13:DB01347 n14:60921
n3:mechanismOfAction
Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
n3:synonym
GR-138950C Saprisartan potassium Saprisartan GR-138950
n3:IUPAC-Name
n4:271B40C6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B40CC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B40CB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B40C8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B40C9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B40CA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B40C4-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B40C5-363D-11E5-9242-09173F13E4C5 n4:271B40C2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B40C3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B40D2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B40D3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B40CD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B40CE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B40D0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B40CF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B40D1-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
146623-69-0
n3:Bioavailability
n4:271B40D8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40DA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40DB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B40D7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B40D6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40D9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B40C7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B40D4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B40D5-363D-11E5-9242-09173F13E4C5